ASH 2010 Deferasirox does not appear to interfere with Cyclosporin
1826 The Oral Iron Chelator Deferasirox for Treatment of Transfusional Iron Overload After Allogeneic Hematopoietic Cell Transplantation Does Not Appear to Interfere with the Calcineurin Inhibitor Cyclosporin Trough Serum Levels
The study deals with the safety of concomitant management of cyclosporin and Exjade after SZT.
Many patients that have undergone SZT have an transfusional iron overload that contributes to treatment-related morbidity and mortality of transplantation. Iron chelation eliminates that overload. But typically these patients have immunsuppressive medication e.g. Cyclosporin. Here the "trough serum cyclosporin level (TSCL)" has to be managed. The data of the study demonstrate, that adequate management of TSCL and iron chelation per deferasirox go together, that Exjade does not change the TSCL.
Citation: "In conclusion, our data demonstrate clearly that maintaining an adequate TSCL in transplanted patients is not complicated by the concomitant treatment with deferasirox."
Margarete, 54, living in Vienna, Austria,
MDS/AML M2, diagnosed 9/2007, then Chemos, aSZT 4/2008, chronic GVHD
|Thread Tools||Search this Thread|
|Thread||Thread Starter||Forum||Replies||Last Post|
|Abstract from the ASH Conference 2010||Birgitta-A||News and Events||27||Tue Dec 28, 2010 01:03 PM|
|ASH 2010 ICT with DFX in Transfusion Dependent MDS||akita||Transfusions and Iron Overload||0||Wed Dec 15, 2010 05:51 PM|
|ASH 2010 Combining Chelators DFO and DFX||akita||Transfusions and Iron Overload||0||Wed Dec 15, 2010 04:43 PM|
|ASH 2010 Iron Overload Accelerates Development of Leukaemia - Mouse Model||akita||Transfusions and Iron Overload||0||Sat Dec 11, 2010 04:21 PM|
|ASH 2010 Hematologic Responses in MDS Patients - Deferasirox/Exjade||akita||Transfusions and Iron Overload||0||Fri Dec 10, 2010 04:14 PM|